Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.

Wu LM, Wang YX, Zhan Y, Liu AH, Wang YX, Shen HF, Wang YF, Wang LY, Tao ZB, Wang YQ

Peptides8 Aug 2021Cited by 32 (Europe PMC)

PMID34375684DOI10.1016/j.peptides.2021.170624PepBankPUB-34375684

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with PCOS, body weight decreased after treatment with different dulaglutide concentrations.
In plain wordsIn rats with PCOS, weight decreased after treatment with different dulaglutide concentrations.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
After treated with different concentrations of dulaglutide, we found that the body weight of rats in the treatment groups were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568401
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with PCOS, dulaglutide decreased serum androgen compared with the PCOS group.
In plain wordsIn rats with PCOS, dulaglutide lowered blood androgen compared with the PCOS group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSerum androgen
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Comparator
PCOS model group
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
Compared with the rats in PCOS group, the serum androgen level of rats in the treatment groups was significantly decreased, and the serum sex hormone binding protein content was significantly increased, and there was statistically significant difference between these groups and PCOS group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568402
03AnimalAnimal study (in vivo)Mechanism
In rats with PCOS, dulaglutide increased serum sex hormone binding protein compared with the PCOS group.
In plain wordsIn rats with PCOS, dulaglutide increased blood sex hormone binding protein compared with the PCOS group.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSerum sex hormone binding protein
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Comparator
PCOS model group
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
Compared with the rats in PCOS group, the serum androgen level of rats in the treatment groups was significantly decreased, and the serum sex hormone binding protein content was significantly increased, and there was statistically significant difference between these groups and PCOS group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568403
04AnimalAnimal study (in vivo)Mechanism
In rats with PCOS, dulaglutide decreased ovarian 3βHSD expression compared with the PCOS group.
In plain wordsIn rats with PCOS, dulaglutide lowered ovarian 3βHSD expression compared with the PCOS group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseOvarian 3βHSD expression
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Comparator
PCOS model group
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
In terms of protein expression and gene regulation, the expression of 3βHSD, CYP19α1 and StAR in the ovarian tissue of rats in treatment groups were decreased significantly after received the treatment of dulaglutide, and there was statistically significant difference between these groups and PCOS group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568404
05AnimalAnimal study (in vivo)Mechanism
In rats with PCOS, dulaglutide decreased ovarian CYP19α1 expression compared with the PCOS group.
In plain wordsIn rats with PCOS, dulaglutide lowered ovarian CYP19α1 expression compared with the PCOS group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseOvarian CYP19α1 expression
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Comparator
PCOS model group
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
In terms of protein expression and gene regulation, the expression of 3βHSD, CYP19α1 and StAR in the ovarian tissue of rats in treatment groups were decreased significantly after received the treatment of dulaglutide, and there was statistically significant difference between these groups and PCOS group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568405
06AnimalAnimal study (in vivo)Mechanism
In rats with PCOS, dulaglutide decreased ovarian StAR expression compared with the PCOS group.
In plain wordsIn rats with PCOS, dulaglutide lowered ovarian StAR expression compared with the PCOS group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseOvarian StAR expression
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Comparator
PCOS model group
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
In terms of protein expression and gene regulation, the expression of 3βHSD, CYP19α1 and StAR in the ovarian tissue of rats in treatment groups were decreased significantly after received the treatment of dulaglutide, and there was statistically significant difference between these groups and PCOS group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568406
07AnimalAnimal study (in vivo)Mechanism
In rats with PCOS, dulaglutide reduced ovarian insulin content.
In plain wordsIn rats with PCOS, dulaglutide reduced insulin content in the ovaries.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseOvarian insulin content
Study
ratn: not reported in source
DHEA-induced PCOS in female SD rats
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated · subcutaneous · 3 weeksAs given in this study (rat).
Source sentences
Summary
In addition, dulaglutide reduced the insulin content in the ovarian tissue of PCOS rats.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the PCOS model was established by giving female SD rats subcutaneous injection of DHEA for 21 consecutive days. After modeling, the treatment group was injected subcutaneously with three doses of dulaglutide for 3 weeks. The model group was injected with sterile ultrapure water, and t…
Report a problemFND-3437568407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords